profit from every €100 of sales.
€0€100
EL.En.
€16.53+2.04% today
+21.5% since Dec 18, 25
1-year low €11.501-year high €17.48
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €30.54 for every €1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What EL.En. sold, what it kept, and what it did with the cash.
Sales went from €674 million in 2022 to €591 million in 2025, with €43.4 million of profit last year.
SalesProfit
EL.En. handed back 36% of the cash it generated last year.
€19M
Free cash flow 2025€59M
Bought back its own shares€2M
Paid as dividends€19M
Cash vs. debt€174M vs. €38M
EL.En. vs. similar companies
EL.En. grows the slowest of these 5 and is priced in the middle for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| EL.En. | 30.5× · Expensive | ||
 Abbott Laboratories | 29.0× · Fair price | ||
 Medtronic | 27.1× · Fair price | ||
 Stryker | 37.4× · Expensive | ||
 Edwards Lifesciences | 56.7× · Expensive |
AI analysis
An AI analyst reads EL.En.'s last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 674 | 576 | 566 | 591 | |
| 243 | 230 | 239 | 254 | |
| 75 | 74 | 72 | 72 | |
| 89 | 88 | 97 | 85 | |
| 55 | 48 | 52 | 43 | |
| 0.69 | 0.60 | 0.64 | 0.54 | |
| 36.1% | 39.9% | 42.2% | 42.9% | |
| 11.2% | 12.8% | 12.7% | 12.2% | |
| 8.2% | 8.4% | 9.1% | 7.3% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 736 | 719 | 741 | 628 |
| Cash | 163 | 131 | 147 | 174 |
| Total debt | 83 | 74 | 47 | 38 |
| Total liabilities | 392 | 344 | 330 | 200 |
| 313 | 346 | 385 | 412 | |
| 80 | 80 | 80 | 80 | |
| 15.2% | 14.3% | 15.0% | 12.7% | |
| 17.6% | 13.9% | 13.4% | 10.5% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2 | 12 | 83 | 71 | |
| 18 | 14 | 9 | 12 | |
| -16 | -1 | 74 | 59 | |
| Dividends paid | 17 | 19 | 17 | 19 |
| 0 | 0 | 5 | 2 | |
| 2 | 2 | 3 | 2 |
Valuation
- 30.5×
- –
- –
- 3.2×
- 2.2×
- 22.4×
- 13.9×
- 4.5%
- 3.3%
- 1.4%
Profitability
- 42.9%
- 12.2%
- 7.3%
- –
- 12.7%
- 14.3%
- –
- –
- –
- –
Growth
- −4.3%
- −7.8%
- –
- –
- +0.1%
Financial health
- -1.6×
- 0.09
- –
- 87.3×
- 3.10
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 20%of 945
Top 42%of 868
Bottom 46%of 555
Bottom 10%of 866
Top 23%of 985
1.4%of the share price, paid each year
On $1,000 invested$14a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
43.1% of its profit
Room to growStretchedMore than it earns: 31.6%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
65Pass
Benjamin Graham
54No pass
Philip Fisher
42No pass
Peter Lynch
23No pass
Joel Greenblatt
35No pass
Charlie Munger
51No pass
Terry Smith
47No pass
Questions about EL.En.
Is EL.En. a good stock to buy?
A business with weak numbers, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the EL.En. AI analysis
What does EL.En. do?
EL.En. S.p.A. engages in the production, research and development, distribution, and sale of laser systems in Italy, Rest of Europe, and internationally. The company offers laser systems for the medical sector and the industrial sector. It is in Medical Devices, based in Calenzano, FI, Italy, with 1,345 employees.
Does EL.En. pay a dividend?
Yes. At today's price the dividend is 1.4% a year, about 43% of its yearly profit. In 2025 it paid out €18.7 million in dividends.
Is EL.En. stock halal?
Yes. EL.En. passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
Who are EL.En.'s competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with EL.En.'s.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.